A Biological Framework for Multiple Sclerosis
MS can be considered a spectrum, researchers proposed
Source: medpagetoday.com
📰 Bruce Cree News
Bruce Cree News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Bruce Cree. Real-time updates on events, politics, business and more.
Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
Sustained efficacy was confirmed with an annualized relapse rate of 0.098 and 67% of patients were relapse-free at six years Safety was consistent with prior findings and the established safety...
Source: marketscreener.com
Bristol Myers: positive results in multiple sclerosis -February 29, 2024 at 08:08 am EST
Bristol Myers Squibb today announced new results from a Phase 3 trial, demonstrating the long-term efficacy and safety profile of Zeposia in patients with relapsing forms of multiple sclerosis . In...
San Francisco United States Bruce Cree University Of California Weill Institute For Neuroscience Bristol Myers Squibb
Source: marketscreener.com
KYV-101 Multiple Sclerosis Treatment Gets FDA Clearance - Physical Therapy Products
A study will seek to answer whether CAR T-cell therapy using KYV-101 offers a new treatment option for patients living with MS.
Source: ptproductsonline.com
Ozanimod for Relapsing MS Shows Long-Term Safety, Efficacy
"Serious infections did not vary by age, and there were too few serious events to identify any age-related trends by specific TEAE," the authors reported.
Source: medscape.com
Horizon Therapeutics plc: New Analysis of MRI Findings Show UPLIZNA (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic
Source: finanznachrichten.de
New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with NMOSD. These findings are being presented during the 49th an...
Source: pharmiweb.com
Horizon Therapeutics plc: New Data Suggest UPLIZNA (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood Vaccines
-- Analyses suggest the B-cell-depleting mechanism of UPLIZNA did not interfere with important immune activity, including COVID-19 infection defenses and antibody levels from childhood vaccines -- Horizon
Source: finanznachrichten.de
Stem Cell Therapy Strikes Out in Progressive MS
Autologous hematopoietic stem cell therapy does not outperform disease-modifying therapy in patients with multiple sclerosis, two new studies suggest.
Tomas Kalincik Sanofi Genzyme Bruce Cree University Of Melbourne Research In Multiple Sclerosis Clinical Outcomes Research Unit
Source: medscape.com
More Evidence for Epstein-Barr Virus' Role in MS
New research goes "a step further" than previous studies by revealing a population of T cells in multiple sclerosis that may be responding directly to EBV during active viral disease, experts say.
United States San Francisco Tilman Schneider Hohendorf Bruce Cree University Of California Research In Multiple Sclerosis
Source: medscape.com